{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:08:39Z","timestamp":1793275719847,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.metabol.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T05:30:35Z","timestamp":1399699835000},"page":"1071-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis"],"prefix":"10.1016","volume":"63","author":[{"given":"Bronwyn G.A.","family":"Stuckey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Opie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Cussons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2014.05.004_bb0010","series-title":"Polycystic ovary syndrome","first-page":"337","author":"Zawadski","year":"1992"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Consensus Statement: revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"issue":"11","key":"10.1016\/j.metabol.2014.05.004_bb0025","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.05.004_bb0030","series-title":"Statistical Methods and Practical Issues","article-title":"Factor analysis","author":"Kim","year":"1978"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.1999.tb07783.x","article-title":"Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players","volume":"892","author":"Zimmet","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.metabol.2014.05.004_bb0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.numecd.2006.09.003","article-title":"How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study","volume":"17","author":"Mannucci","year":"2007","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0045","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/diacare.29.02.06.dc05-1478","article-title":"Clustering of cardiovascular risk factors associated with the insulin resistance syndrome\u2014Assessment by principal component analysis in young hyperandrogenic women","volume":"29","author":"Zanolin","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2014.05.004_bb0050","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1210\/jc.2010-0334","article-title":"Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism","volume":"95","author":"Dewailly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2014.05.004_bb0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1210\/jcem-67-3-460","article-title":"Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin","volume":"67","author":"Plymate","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-72-1-83","article-title":"A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome","volume":"72","author":"Nestler","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1056-8727(01)00191-X","article-title":"The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states","volume":"16","author":"Rashid","year":"2002","journal-title":"J Diabetes Complications"},{"issue":"4","key":"10.1016\/j.metabol.2014.05.004_bb0070","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"issue":"7","key":"10.1016\/j.metabol.2014.05.004_bb0075","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.metabol.2008.02.011","article-title":"An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet","volume":"57","author":"Glueck","year":"2008","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2014.05.004_bb0080","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1210\/jc.2007-0190","article-title":"Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome","volume":"92","author":"Luque-Ramirez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.05.004_bb0085","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.106.083972","article-title":"Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome","volume":"49","author":"Chen","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ecl.2011.01.009","article-title":"Ovarian hypertension: polycystic ovary syndrome","volume":"40","author":"Bentley-Lewis","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.metabol.2014.05.004_bb0095","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1047-2797(97)00123-3","article-title":"Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women","volume":"8","author":"Shelley","year":"1998","journal-title":"Ann Epidemiol"},{"issue":"4","key":"10.1016\/j.metabol.2014.05.004_bb0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0950-351X(05)80082-5","article-title":"Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids","volume":"4","author":"Crook","year":"1990","journal-title":"Baillieres Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2014.05.004_bb0110","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/endo.138.9.5404","article-title":"Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes","volume":"138","author":"Croston","year":"1997","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.fertnstert.2008.06.004","article-title":"Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels","volume":"92","author":"Fruzzetti","year":"2009","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.metabol.2014.05.004_bb0120","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1210\/jcem.83.8.5041","article-title":"The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome","volume":"83","author":"Diamanti-Kandarakis","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"4 Pt 1","key":"10.1016\/j.metabol.2014.05.004_bb0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0895-7061(00)01280-2","article-title":"Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass","volume":"14","author":"Keulen","year":"2001","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2006.01.079","article-title":"Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States","volume":"98","author":"Wong","year":"2006","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.metabol.2014.05.004_bb0135","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/euhj.2001.2888","article-title":"Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55years) men and women","volume":"23","author":"Thomas","year":"2002","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.metabol.2014.05.004_bb0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1050-1738(02)00187-1","article-title":"Addressing the insulin resistance syndrome: a role for the thiazolidinediones","volume":"12","author":"Zimmet","year":"2002","journal-title":"Trends Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.metabol.2014.05.004_bb0145","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/humrep\/den263","article-title":"Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome","volume":"23","author":"Cussons","year":"2008","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.metabol.2014.05.004_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF03348715","article-title":"Gonadotropin evaluation in the diagnosis of polycystic ovary syndrome using either a monoclonal or a polyclonal antibody radioimmunoassay","volume":"15","author":"Manieri","year":"1992","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0155","first-page":"119","article-title":"Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome","volume":"79","author":"Apter","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1471-0528.2009.02383.x","article-title":"Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropin-releasing hormone secretion","volume":"117","author":"Burt Solorzano","year":"2010","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.metabol.2014.05.004_bb0165","first-page":"3728","article-title":"Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity","volume":"82","author":"Arroyo","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0170","first-page":"131","article-title":"Incidence of elevated LH\/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia","volume":"48","author":"Banaszewska","year":"2003","journal-title":"Rocz Akad Med Bialymst"},{"issue":"4","key":"10.1016\/j.metabol.2014.05.004_bb0175","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.fertnstert.2008.01.036","article-title":"Inappropriate gonadotropin secretion in polycystic ovary syndrome","volume":"91","author":"Hsu","year":"2009","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.metabol.2014.05.004_bb0180","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.fertnstert.2003.05.010","article-title":"Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome","volume":"80","author":"Moran","year":"2003","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.metabol.2014.05.004_bb0185","first-page":"1328","article-title":"Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women","volume":"79","author":"Barnes","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.05.004_bb0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2265.1990.tb00857.x","article-title":"Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases","volume":"32","author":"Kiddy","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.metabol.2014.05.004_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/eje.1.02058","article-title":"Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS","volume":"154","author":"Carmina","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2014.05.004_bb0200","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3945\/ajcn.110.005538","article-title":"Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial","volume":"93","author":"Phelan","year":"2011","journal-title":"Am J Clin Nutr"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:04:07Z","timestamp":1758427447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514001449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0026049514001449"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.05.004","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}